Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"? - Test2 - elhamkhani - TriplyDB

Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?

Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?

http://www.wikidata.org/entity/Q31138845

about

Potential therapeutic interest of adenosine A2A receptors in psychiatric disorders.Role of Sirtuins in Linking Metabolic Syndrome with Depression Obesity and Its Potential Effects on Antidepressant Treatment Outcomes in Patients with Depressive Disorders: A Literature Review Neuroinflammation and comorbidities are frequently ignored factors in CNS pathology Glucocorticoid regulation of inflammation and its functional correlates: from HPA axis to glucocorticoid receptor dysfunction Molecular and Genetic Characterization of Depression: Overlap with other Psychiatric Disorders and Aging Role of neuroinflammation in neurodegenerative diseases (Review)Leukocyte telomere length in major depression: correlations with chronicity, inflammation and oxidative stress--preliminary findings Peripheral telomere length and hippocampal volume in adolescents with major depressive disorder.Diabetes mellitus and disturbances in brain connectivity: a bidirectional relationship?Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide.Influence of depression on genetic predisposition to type 2 diabetes in a multiethnic longitudinal study.Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders.The Methylation Capacity of Arsenic and Insulin Resistance are Associated with Psychological Characteristics in Children and Adolescents.Cardiometabolic Health in Bipolar Disorder Biological substrates underpinning diagnosis of major depression.Basal ganglia morphology links the metabolic syndrome and depressive symptoms.Medical comorbidity in bipolar disorder: relationship between illnesses of the endocrine/metabolic system and treatment outcome The development of an RDoC-based treatment program for adolescent depression: "Training for Awareness, Resilience, and Action" (TARA)Biological mechanisms underlying the role of physical fitness in health and resilience.Psychological symptoms and insulin sensitivity in adolescents Association of sleep duration and insulin resistance in Taiwanese vegetarians.Metabolic syndrome and metabolic abnormalities in patients with major depressive disorder: a meta-analysis of prevalences and moderating variables.Risk-assessment and coping strategies segregate with divergent intrinsic aerobic capacity in rats.Inflammatory modulation of exercise salience: using hormesis to return to a healthy lifestyle Up-regulation of leucocytes genes implicated in telomere dysfunction and cellular senescence correlates with depression and anxiety severity scores.Adolescent girls with emotional disorders have a lower end-tidal CO2 and increased respiratory rate compared with healthy controls.Fasting Blood Glucose and Depressive Mood among Patients with Mental Illness in a Medicaid Managed Care Program A study of sociodemographic clinical and glycemic control factors associated with co-morbid depression in type 2 diabetes mellitus.Of sound mind and body: depression, disease, and accelerated aging Longitudinal study of depressive symptoms and progression of insulin resistance in youth at risk for adult obesity The mechanisms by which antidepressants may reduce coronary heart disease risk Association of coexisting diabetes and depression with mortality after myocardial infarction.Bidirectional association between depression and metabolic syndrome: a systematic review and meta-analysis of epidemiological studies.The risk of developing type 2 diabetes mellitus associated with psychotropic drug use in children and adolescents: a retrospective cohort analysis.Prefrontal cortical deficits in type 1 diabetes mellitus: brain correlates of comorbid depression A review of electroencephalographic changes in diabetes mellitus in relation to major depressive disorder.Surgical treatment of Charcot neuropathy.NPAS2 and PER2 are linked to risk factors of the metabolic syndrome.Dietary treatment options for depression among diabetic patient, focusing on macronutrients

P2860

Q24657796-EAA6BE34-EF1A-4E8A-B716-AE269B4F421B Q26749937-CB900B5E-18A1-4B65-93F8-12A63016C0C9 Q26771735-F95EE7E1-3A43-4105-A8CC-B7710FA516DB Q26775794-89FFCE85-086A-4C59-8B5E-F7C29ABFF50A Q27024383-04D81E0D-B262-41C0-9A37-03B761AFE112 Q27345087-048CF67D-34F7-40B3-BEF1-8B6BB33F1080 Q28080292-B0150481-6D59-4AD8-A4C5-5A668DFBB0B5 Q28741691-E4C68EF9-748C-479F-A6D5-A05C413FB928 Q30823843-FCBD4F96-24A4-4A92-9A36-A0DB90142B5E Q30833828-14903389-21DC-4D36-B391-7DDBA12293DC Q33442474-A28470A0-3CFB-4A7A-84FA-09994C1E710E Q33686311-75FF7670-0F1C-4493-9266-94EF6EF15D15 Q33721019-B8673415-363C-4CDB-A44B-69314FA2E2C4 Q33779996-88C70613-E4A8-482E-8CB3-2DC003C47628 Q33795131-633CEDC7-A9BF-4F1E-B391-A7D2281E11AA Q33820463-376F1E51-D1FA-45B9-B8FC-408280EC3D24 Q33986931-470DA653-8087-484E-9095-2F3837EF8974 Q34034971-26A75A69-8DE8-41CC-9BF0-B2ECF76DD788 Q34063322-4A2F7F20-0FA4-42A7-A734-0F925F01D8FD Q34079375-EF4334EC-1915-49F9-A287-FE346A65D3D9 Q34140559-9EB07CFD-0BE2-46C1-B40E-03E5145609F2 Q34381850-2EF6A994-FAA7-4088-892C-D7A6126EBFEF Q34386877-F2EAB57E-D43B-4489-9FDF-B5DB22F5EFC5 Q34424642-7821DFD7-CBAC-4E54-86E9-373A0DEE1621 Q34439287-A77FC3A0-020F-403F-B7A3-3EFB813A0886 Q34490369-DA05D30D-B0AA-4918-9590-6456598622CF Q34853976-A0FF5B5F-13DD-47BC-91C3-E0DA658B19A3 Q35070701-D70F3F50-D818-4498-8385-C4770ACA17F7 Q35183240-196A31F4-0B1B-4CD9-8AA6-D24CC34A634E Q35237227-5A4B1B52-0512-46C3-8E0C-D862B56C3CE0 Q35408515-DBEFB9E6-3274-4220-90CF-EFA4F9802145 Q35731801-5C826074-B796-45C5-B816-7A2E4E8D0C93 Q35879076-49C41A5C-F3C6-4B22-9540-F01C323F9B57 Q35898326-1A59E262-59B8-4EBF-87D7-2038D6FD7A7B Q35977762-F3FCE05E-69F0-43FB-8BFF-0C4A6EFEF019 Q36377600-2E938F61-8754-4DFB-BC1E-EF860970B7CD Q36555366-7F17F435-7968-4ED4-8331-51A1A20127B3 Q37177218-42EED6DF-9A03-4FB7-B580-ABA4935E6747 Q37229372-9596B3AC-7E6A-42CB-A78A-D79A2A50ECCC Q37250144-1306F4BC-D465-4A10-8813-F61599C2BFCB

P2860

Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?

http://www.wikidata.org/entity/Q31138845

description

2007 nî lūn-bûn

@nan

2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?

@ast

Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?

@en

type

label

Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?

@ast

Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?

@en

prefLabel

Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?

@ast

Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?

@en

P1433

Q31138845-C4F7CABE-15A8-4A62-BC2E-138A5989D940

P1476

Q31138845-26A8A334-ADF2-4445-9CDE-C0DB65A154F1

P2093

Q31138845-1320B3F2-CCB0-4708-84C3-31E2A018969F

Q31138845-160F0C97-E5FF-4351-81B0-6EA2520E4CCC

Q31138845-19650E36-2713-460B-9ACF-5B2AD7C0AEFB

Q31138845-2066A8DF-CD66-4733-9A18-B839CFF4F6D1

Q31138845-3195E1B8-C04A-47F7-BBF4-1B5E5A1CF114

Q31138845-A9D4FF0B-4A64-4014-8C99-247952412B16

Q31138845-BA099338-8F2A-4848-AE4E-E8DC1786BFE1

P304

Q31138845-7C366406-1007-4F1F-8923-5813ACB295E1

P31

Q31138845-F145E67A-1169-497B-8321-D5F3426DB0DA

P356

Q31138845-150576CD-C013-4F34-9B2E-2351DE334B2F

P433

Q31138845-E46564FC-45C4-456F-AC91-D4BB502B213C

P478

Q31138845-697965DB-BE6D-4918-92DE-8153F58FB96B

P50

Q31138845-6473E21B-4A59-4F06-BE57-8DD175FDF2D0

P577

Q31138845-9955ACFD-00FA-467A-B6E6-998CAA61F22A

P5875

Q31138845-7101A036-0CAA-4515-A529-971B645549E4

P698

Q31138845-4A6C8004-FD99-4D95-8EED-C6F018C8A902

P921

Q31138845-5AECEC59-019E-40B4-B94B-B1E05BD420FF

P356

10401230701653377

P1433

Annals of Clinical Psychiatry

P1476

Should Depressive Syndromes Be Reclassified as "Metabolic Syndrome Type II"?

@en

P2093

Andrew Miranda

http://www.w3.org/2001/XMLSchema#string

Candy W Y Law

http://www.w3.org/2001/XMLSchema#string

Don Fulgosi

http://www.w3.org/2001/XMLSchema#string

Hanna O Woldeyohannes

http://www.w3.org/2001/XMLSchema#string

Jakub Z Konarski

http://www.w3.org/2001/XMLSchema#string

Roger S McIntyre

http://www.w3.org/2001/XMLSchema#string

Sidney H Kennedy

http://www.w3.org/2001/XMLSchema#string

P304

257-264

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/10401230701653377

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

19

http://www.w3.org/2001/XMLSchema#string

P50

Joanna K Soczynska

P577

2007-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5790535

http://www.w3.org/2001/XMLSchema#string

P698

18058283

http://www.w3.org/2001/XMLSchema#string

P921

metabolic syndrome